Doubts over landmark heart drug trial: ticagrelor PLATO study

A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, <b>Peter Doshi</b> takes a fresh look at the evidence

Authors

Institutions

Publication Details

Journal
BMJ
Published
2024-12-11
DOI
https://doi.org/10.1136/bmj.q2550
Citations
9
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
3.62
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Doubts over landmark heart drug trial: ticagrelor PLATO study

Peter Doshi
9 citations
BMJ
Antiplatelet Therapy and Cardiovascular Diseases
3.62
article

Doubts over landmark heart drug trial: ticagrelor PLATO study

Peter Doshi
article en
9 citations

Abstract

A top selling antiplatelet drug has never quite shaken off doubts about its advantage over cheaper rivals. With generic versions of ticagrelor about to launch, <b>Peter Doshi</b> takes a fresh look at the evidence

BMJVol. 387
BMJ Group (United Kingdom)
Openalex Percentile: Top 6%
Antiplatelet Therapy and Cardiovascular Diseases
3.62
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Doubts over landmark heart drug trial: ticagrelor PLATO study — Peter Doshi · BMJ (2024) | TGRS Research Map | TGRS